{"id":2070,"date":"2023-10-13T01:13:58","date_gmt":"2023-10-12T22:13:58","guid":{"rendered":"https:\/\/www.sightsciences.com\/us\/?p=2070"},"modified":"2024-07-10T17:43:34","modified_gmt":"2024-07-10T14:43:34","slug":"sight-sciences-announces-presentation-of-successful-phase-i-results-of-the-sahara-randomized-controlled-clinical-trial-comparing-tearcare-to-restasis","status":"publish","type":"post","link":"https:\/\/www.sightsciences.com\/us\/sight-sciences-announces-presentation-of-successful-phase-i-results-of-the-sahara-randomized-controlled-clinical-trial-comparing-tearcare-to-restasis\/","title":{"rendered":"Sight Sciences Announces Presentation of Successful Phase I Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare\u00ae to Restasis\u00ae for the Treatment of Dry Eye Disease at the American Academy of Optometry Annual Meeting"},"content":{"rendered":"
\n
\n
\n
\n
<\/div>\n
\n
\n
PDF Version<\/a><\/span><\/div>\n

 <\/p>\n

\n
<\/div>\n

Interventional eyelid procedures enabled by TearCare technology successfully delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through six months<\/h3>\n

 <\/p>\n

MENLO PARK, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (\u201cSight Sciences,\u201d or the \u201cCompany\u201d), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients\u2019 lives, today announced the presentation of the full phase I results from the SAHARA randomized controlled trial (\u201cRCT\u201d), demonstrating that interventional eyelid procedures for dry eye disease enabled by TearCare technology (\u201cTearCare\u201d) were superior at all measured time points to Restasis prescription eyedrops (\u201cRestasis\u201d) for the improvement of tear break up time (\u201cTBUT\u201d), the trial\u2019s primary objective endpoint and a key measure of aqueous retention, tear stability and the tear film\u2019s ability to protect the ocular surface. TearCare and Restasis also delivered comparable clinically and statistically significant improvements at every time point measured in patient reported outcomes measured by Ocular Surface Disease Index (\u201cOSDI\u201d) scores, the trial\u2019s primary subjective endpoint.<\/p>\n

 <\/p>\n

These results were presented today at the American Academy of Optometry\u2019s annual meeting in New Orleans. \u201cPharmaceutical intervention with Restasis has been the hallmark of dry eye treatment since its introduction. The results of the SAHARA RCT utilizing TearCare technology, which treats the root cause of dry eye disease, should make us rethink our options for the optimal treatment for dry eye,\u201d remarked Dr. Marc R. Bloomenstein, O.D., FAAO, Director of Optometric Services, Schwartz Laser Eye Center, and a Principal Investigator for the SAHARA clinical trial. \u201cKnowing we can achieve superior dry eye results with a procedure that also reduces concerns for daily prescription eyedrop patient compliance and adherence should make my colleagues in eyecare, as well as insurance providers, consider providing our patients access to TearCare as an efficacious and durable interventional dry eye treatment.\u201d<\/p>\n

 <\/p>\n

The study also demonstrated that TearCare was superior to Restasis in several other important objective signs of dry eye and delivered statistically significant improvements from baseline in all other measures that were at least as good as Restasis at all measured time points. SAHARA included 345 subjects at 25 sites in 14 states randomized 1:1 between TearCare and Restasis groups. Results are expected to be published in a peer-reviewed journal in late 2023.<\/p>\n

 <\/p>\n

SAHARA Phase I Complete Results:<\/strong><\/p>\n

 <\/p>\n